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Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease, which causes synovial damage.
Persistence of lymphocyte infiltrates in the rheumatoid synovium has been attributed to abnormal apoptosis. While
not comprehensively investigated, perturbations in peripheral blood lymphocyte (PBL) apoptosis may also be
involved in perpetuation of autoimmune processes in RA.
Methods: We investigated total, CD4+ and CD19+ PBL apoptosis in our study cohort by monitoring the
translocation of phosphatidylserine using the Annexin-V assay. To examine the role of death receptor mediated
apoptosis as well as activation-induced-cell-death (AICD), PBLs were labeled with CD95/Fas and CD69 markers and
enumerated by flow cytometry. Proteolytic activity of initiator and executioner caspases was determined by
luminometry. DNA fragmentation assays were used to examine whether apoptotic signals were transduced to the
nucleus. Quantitative PCR arrays were used to investigate apoptotic pathways associated with RA-PBLs. Since heat-
shock-protein-70 (HSP70) is an inducible protein which modulates apoptotic signals, we determined HSP70 levels
by intra-cellular flow cytometry and western blots.
Results: The RA-PBLs showed signs of elevated apoptosis whilst in circulation. These include increases in the loss
of plasma membrane asymmetry, indicated by increased externalization of phosphatidylserine (especially in B-
lymphocytes). RA-PBLs showed a bias to CD95/Fas mediated apoptotic pathways, but low levels of the CD69
marker suggested that this was not associated with immune activation. Although downstream markers of
apoptosis such as caspase-3/7 activity, were increased, no DNA fragmentation was observed in RA-PBLs.
Interestingly, elevated levels of apoptosis did not correlate with absolute lymphocyte counts in RA patients. Levels
of HSP70 were highly elevated in RA-PBLs compared to controls.
Conclusion: The results suggest that while apoptosis may be initiated in RA-PBLs, they may lack commitment to
fully executing the apoptotic program. This may be related to inhibition on apoptotic transduction by HSP70. This
study provides evidence that abnormalities in RA-PBLs apoptosis may occur whilst still in circulation and may
contribute to pathogenesis of the disease.
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Rheumatoid arthritis (RA) is an autoimmune disease
characterized by chronic joint inflammation, synovial
hyperplasia and bone erosion. In RA, the synovial micro-
environment is considerably altered due to secretion of
pro-inflammatory cytokines and subsequent infiltration
of inflammatory cells. This facilitates pannus tissue for-
mation and invasive growth of synovial tissue into articu-
lar cartilage and bone, with eventual joint destruction [1].
Bone and cartilage erosion occur during the natural
progression of RA as a result of subtle underlying abnorm-
alities in immune regulation and function. Accumulation
and persistence of the lymphocyte infiltrate in the rheuma-
toid synovium are characteristic features of the disease [2].
In normal inflammatory responses, lymphocytes are elimi-
nated, upon cessation of function, by initiation of apopto-
tic cascades [3]. Apoptosis is the major mechanism of
programmed cell death and is necessary for regulation of
tissue growth and homeostasis. In particular, the immune
system relies heavily on apoptosis to ameliorate inflamma-
tion in order to prevent misdirected damage to normal
tissue [4].
Several lines of evidence in RA suggest that malfunc-
tions in apoptosis are responsible not only for the persis-
tence of synovial lymphocytes, but also for the invasive
nature of fibroblast-like-synoviocytes (FLS) [5,6]. Interac-
tions between these cell types either through cellular
contact or by secretion of soluble factors contribute to
impaired apoptosis and chronic inflammation of the
synovial membrane [7].
In murine models of proteoglycan induced arthritis, T-
lymphocyte apoptosis was shown to be defective despite
high expression levels of CD95/Fas and was related to
impaired downstream CD95/Fas signaling pathways [8].
Elevated levels of anti-apoptotic Bcl-2 proteins conferred
resistance to CD95/Fas-induced apoptosis in CD4
+
T-lymphocytes from RA patients [9]. Furthermore, it was
shown that RA-FLS synthesize high quantities of stro-
mal-cell-derived-factor-1a (SDF1a), a ligand for lympho-
cyte chemokine-receptor-4 (CXCR4), which induces
migration of CD4
+ T-lymphocytes to the synovium.
Interestingly, SDF1a also inhibits T-lymphocyte apopto-
sis by interfering with mitogen-activated-protein-kinase
(MAPK) pathways [10].
In addition to T-lymphocytes, there is growing interest
in B-lymphocyte biology within the context of autoim-
munity [11]. The recent success of anti-B-lymphocyte
therapies support the notion that breakdown of normal
B-lymphocyte function contributes to the pathogenesis of
RA [12]. Indeed, there is accumulating evidence for
impaired B-lymphocyte apoptosis in the rheumatoid
synovium [13]. B-lymphocytes are enriched in the RA
synovial membrane and are bound to FLS, which act as
follicular dendritic cells [14]. In co-culture with RA syno-
vial stromal cells, B-lymphocytes up-regulate expression
of Bcl-xL, which inhibits mitochondrial pro-apoptotic
signals [15]. Inhibition of B-lymphocyte apoptosis by FLS
was shown to occur in a cell-contact dependant manner
via vascular-cell-adhesion-molecule-1 (VCAM1) [16].
These data suggest that cell-contact interactions contri-
bute to the pathophysiology ultimately leading to
destruction of the rheumatoid synovium.
While synovial joints are the primary sites of inflamma-
tion in RA, there is a significant, but poorly understood
systemic inflammatory component of the disease.
Immuno-pathologies in RA are not limited to synovium
sensitive cells but also involve the majority of circulating
peripheral lymphocytes. Zhang et al (2001) proposed that
defective apoptosis may lead to accumulation of T-lympho-
cytes in peripheral circulation [8]. It is likely that this may
perpetuate the often elusive systemic complications of RA.
There is compelling evidence to show that dysregulation of
PBL apoptosis is critical in the pathogenesis of various sys-
temic autoimmune diseases such as systemic lupus erythe-
matosus (SLE), Sjögrens syndrome and systemic sclerosis
[17,18]. Apoptosis in RA-PBLs however, has not been com-
prehensively investigated. Defects in RA-PBL apoptosis
could clearly underlie some of the characteristic immuno-
logic phenomena seen in RA patients.
Despite an unclear delineation of their specific roles,
stress-response proteins, specifically heat shock proteins
(HSPs), have been repeatedly implicated as key participa-
tors in the pathogenesis of RA [19]. Interestingly, numer-
ous mechanisms of HSP-mediated inhibition of cell death
have been described [20,21]. Since RA-PBLs exist in a
milieu of inflammatory mediators such as tumor-necrosis-
factor-a (TNFa) and C-reactive protein (CRP) [22], it is
likely that exacerbated stress responses may interfere with
transmission of apoptotic signals.
It is generally accepted that the autoimmune manifesta-
tions of RA are due, in part, to impaired lymphocyte apop-
tosis. Whether these defects are related to failures in
executing the apoptotic program at inflammatory sites, or
as a result of inherent defects in lymphocyte apoptotic
machinery prior to recruitment to these sites remain to be
elucidated. The apoptotic status of circulating lymphocytes
in RA may be a useful indicator of underlying pathological
processes or disease activity. A better understanding of
PBL biology, and indeed PBL apoptosis, may provide clues
to how immunological tolerance is breached in RA. Con-
sequently, in this study we investigated whether PBL apop-
tosis was impaired in RA patients directly ex vivo and
whether there was an association with HSP70.
We report that PBL showed early signs of elevated
apoptosis in our patient cohort and seemed to be asso-
ciated with CD95/Fas, but is not necessarily related to
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cantly high levels of PBL apoptosis measured in patients,
absolute lymphocyte counts remained high. In addition,
we did not observe any downstream markers of apoptosis
such as DNA fragmentation in patients. Our data also
shows elevated levels of heat-shock-protein-70 (HSP70),
which correlated with phosphatidylserine externalization.
HSP70 is a known modulator of apoptosis and may inter-
fere with transmission of apoptotic cascades in RA-PBLs.
We suggest that abnormal control of PBL apoptosis may
contribute to autoreactivity in persons who develop RA.
Materials and methods
Patient recruitment
Fifty South African black RA patients attending the
Rheumatology clinic at Inkosi Albert Luthuli Central
Hospital (Durban, South Africa) were recruited into the
study. All patients (mean age: 50.7 years, range 18-75
years; mean duration of disease: 13.3 ± 9.5 years) ful-
filled the American College of Rheumatology (ACR) cri-
teria for RA [23] and were on disease-modifying
antirheumatic drug (DMARD) treatments. Patient
recruitment commenced following institutional ethical
approval (H109/04) and informed consent was obtained
for each patient. The patients reported no recent/
chronic infection or history of other chronic inflamma-
tory diseases. Clinical and laboratory parameters (mean
number of swollen joints and tender joints; erythrocyte
sedimentation rate, ESR; C-reactive protein, CRP; abso-
lute lymphocyte counts) were recorded for all the
patients, (Table 1). An equal number of healthy race
matched control samples were sourced from the South
African National Blood Services following routine
screening. Both control and patient groups had a female
to male ratio of 6:1. Control samples were extracted and
assayed in the same manner as patient samples to
ensure comparability.
Peripheral blood mononuclear cell (PBL) preparation
Buffy coats containing PBL were extracted from hepari-
nized whole blood by differential centrifugation. Briefly,
5 ml whole blood collected from each subject, was
layered onto equivolume Histopaque 1077 (Sigma, Ger-
many) in 15 ml polypropylene tubes. Layered blood was
then centrifuged at 400 × g for 30 minutes. Buffy coats
were aspirated into new polypropylene tubes and washed
twice in phosphate buffered saline (PBS) (400 × g, 10
minutes). Cell density was adjusted to 1 × 10
6 cells/ml
after exclusion of dead cells with trypan blue. Sample
preparation and subsequent apoptosis assays were com-
plete within 3-4hrs after drawing of blood from study
participants.
Detection of phosphatidylserine on outer membrane of
peripheral lymphocytes
The annexin-V-FITC apoptosis detection kit (Roche,
Germany) was used to label apoptotic PBL with translo-
cated phosphatidylserine residues on the outer plasma
membrane. In addition to annexin-V-FITC, the kit con-
tained propidium iodide (PI) which was used to monitor
late stage apoptosis and necrotic cell death. The assay
procedure was as per manufacturer’s instructions. Briefly,
annexin-V-FITC labeling solution (100 μl) was added to
1×1 0
6 PBL in cytometry tubes and allowed to incubate
for 15 minutes in the dark at room temperature (RT).
Following incubation, two separate aliquots of the
annexin-labeled PBL were prepared in order to assess
apoptosis in B- and T-lymphocyte sub-populations. Allo-
phycocyanin (APC)-labeled anti-CD4 and anti-CD19
(Pharmingen, USA) was added (5 μl) to the respective
PBL aliquots 10 minutes prior to enumeration by flow
cytometry.
Detection of CD95/Fas and activation marker CD69 on
peripheral lymphocytes
Aliquots of approximately 1 × 10
5 PBL were transferred
into cytometry tubes containing monoclonal mouse anti-
CD95/Fas (1:100) (Sigma, Germany). The mixture was
allowed to react for 20 minutes and PBL were thereafter
washed in PBS (400 × g, 10 minutes). To detect Fas-posi-
tive PBL by flow cytometry,r a b b i ta n t i - m o u s eA P C -
labeled secondary antibody (Sigma, Germany) was added
to cells at a final dilution of 1:1000 and allowed to react
for 15 minutes. In order to determine the activation status
of circulating lymphocytes in RA patients, 1 × 10
5 PBL
were incubated with 10 μl fluorescein-isothiocyanate
(FITC) labeled anti-CD69 (BD Biosciences) for 15 minutes
prior to analysis by flow cytometry.
Intra-cellular detection of heat shock protein 70 (HSP70)
For each sample, 1 × 10
5 PBL were transferred into cyto-
metry tubes. Cells were then fixed (100 μl Caltag reagent
Table 1 Summary of clinical and laboratory parameters
measured in RA patients
Parameter Result (Mean ± SD)
Mean number of swollen joints 12 ± 6.7
Mean number of tender joints 13 ± 8.7
ESR 42.3 ± 28.5 mm/hr
CRP 19.59 ± 20.5 mg/ml
Mean lymphocyte count 6.9 ± 2.7 × 10
9 /l
Patients Treatments:
Patients on MTX 13
Patients on MTX + steroids 29
Patients on other DMARDs 8
Disease Duration:
< 10 years 22
> 10 years 28
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minutes at RT. After fixation, PBL were washed in PBS
supplemented with 0.1% sodium azide and 5% fetal
bovine serum (300 × g, 5 minutes). Thereafter, PBL were
re-suspended in permeabilization medium (100 μl, Caltag
reagent B permeabilization medium; Caltag Laboratories,
USA) containing monoclonal mouse anti-HSP70 (1:1,
000; Pharmingen, USA) for 30 minutes. Following per-
meabilization and incubation with primary antibody, PBL
were washed twice as previously described. Samples were
then incubated with APC-conjugated rabbit anti-mouse
secondary antibody (1:10, 000; Pharmingen, USA) for 20
minutes at RT in the dark. After an additional wash step,
labeled PBL were re-suspended in sheath fluid for detec-
tion by flow cytometry.
Flow cytometry
PBL were identified and sorted according to forward and
side angle scatter morphological parameters (Figure 1A).
Labeled PBL in the assays above were enumerated by flow
cytometry using a 4-colour FACS Calibur (BD Biosciences,
Belgium) flow cytometer. Data was acquired with Cell-
Quest Pro software (BD Biosciences, Belgium) from 100,
000 events for each assay. Analysis was performed with
FlowJo 7.1 software (Tree Star Inc., USA).
Apoptotic protease activity
Luminometry assays determined the activities of apopto-
tic initiator caspase 9 and executioner caspases 3/7.
Separate aliquots of PBL (1 × 10
5) were transferred into
luminometry-quality white microtitre plates. 100 μlo f
caspase substrate (Caspase-Glo 3/7, Caspase-Glo 9; Pro-
mega, USA) was added to PBL and allowed to react for
30 minutes. Luminescent signals were then measured
with the Modulus microplate luminometer (Turner Bio-
systems, USA) and expressed as relative light units.
Analysis of apoptotic pathways by quantitative PCR
(qPCR) array
RNA was extracted and purified from PBLs using Trizol
reagent (Invitrogen, USA) as per manufacturer’s instruc-
tions and thereafter quantified by spectrophotometry.
Expression of 84 critical genes which represent 10 func-
tional gene groups involved in apoptotic signal transduc-
tion pathways were analyzed by quantitative PCR using
the Human Apoptosis RT
2 Profiler PCR array (SABios-
ciences, USA), according to the manufacturer’s protocol.
Details regarding the technology and specific genes can
be found at the following URL: http://www.sabios-
ciences.com/rt_pcr_product/HTML/PAHS-012A.html.
Briefly, cDNA was prepared from 1 μgo ft o t a lR N A
using the RT
2 PCR array first strand kit (SABiosciences,
USA). qPCR reactions were conducted in a 25 μlm i x -
ture which included 12.5 μlo f2 Xq P C Rm a s t e rm i x ,
11.5 μl of nuclease free water and 1 μlo fc D N At e m -
plate. The thermal cycle profile consisted of an initial
10 minute step at 95°C followed by 40 cycles of 95°C for
15 seconds and 60°C for 1 minute. Real time quantita-
tions were carried out using the Bio-Rad Chromo4 real
time detection system (Bio-Rad, USA). Data was ana-
lyzed using SABiosciences web-based qPCR data analysis
service. Fold changes were calculated using the 2
- ΔΔ Ct
method.
Detection of HSP70 by Western blot
Total PBL protein was extracted from each sample using
Cytobuster™ (Calbiochem, UK) reagent, supplemented
with protease inhibitors, as per manufacturer guidelines.
Protein concentration was determined by the bicincho-
ninic acid assay (Sigma, Germany) and standardized to
250 μg/ml. Samples containing 10 μg of protein were
boiled in Laemmli buffer for 5 minutes and then sub-
jected to electrophoresis in 10% sodium dodecyl sulfate
Figure 1 Flow cytometry scatter plots for the Annexin-V assay. A: PBL were identified and gated based on forward and side scatter
properties. B: Scatter plots for green and red fluorescence channels were used to measure Annexin-V and PI positivity respectively.
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electro-transfered to polyvinylidene difluoride mem-
branes (PVDF). After blocking with Tris-buffered saline
(TBS) containing 5% nonfat dry milk and 0.1% Tween
20, the membrane was immuno-probed with monoclo-
nal anti-HSP70 (1:5, 000; Pharmingen, USA) for 1 hour
at RT. The PVDF membrane was then subjected to 5
washes (10 minutes each) with TBS containing 0.1%
Tween 20. The membrane was then exposed to second-
ary antibody (anti-mouse-horse-radish-peroxidase
(HRP)-conjugate; 1:10, 000; Bio-Rad, USA) for 1 hour at
RT. Anti-b-actin-HRP (Sigma, Germany) was utilized
for internal loading controls. After further washing, anti-
gen-antibody complexes were detected by chemilumi-
nescence using the Immune-star™ HRP substrate kit
(Bio-Rad, USA). Chemiluminescent signals were
detected with the Chemi-doc XRS gel documentation
system. Images were acquired and analyzed with Quan-
tity-one™ image analysis software (Bio-Rad, USA). Data
is represented as peak band intensity for each sample.
DNA fragmentation assay
Genomic DNA was extracted from PBL (1 × 10
5) for each
sample. Cells were transferred to 500 μl lysis buffer con-
taining 0.5% SDS, 150 mM NaCl, 10 mM EDTA, and
10 mM Tris-HCl (pH 8.0). To this RNase A (100 μg/ml;
DNase-free) was added and the solution was incubated at
37°C for 1 hour. Subsequently proteinase K (200 μg/ml)
was added to the solution and incubated for a further 3
hours at 50°C. Protein contaminants were then precipi-
tated by addition of 0.1 volume 5 mM potassium acetate
and centrifugation (5, 000 × g; 15 minutes). Supernatants
containing genomic DNA were transferred to fresh tubes
and extracted with 100% isopropanol on ice, and thereafter
washed with 70% ethanol. DNA samples were then dis-
solved in 10 mM Tris and 0.1 mM EDTA (pH 7.4) at 4°C
overnight. Concentration of each sample was determined
spectrophotometrically. To prepare a positive control for
the DNA fragmentation assay, apoptosis was induced in
control PBL samples by treating with camptothecin (4 μg/
ml, 12 hours) in vitro. DNA was extracted and quantified
as described above. Equal amounts of DNA (300ng) were
electrophoresed (150V; 50 minutes) on a 1.8% agarose gel
containing 0.5 mg/ml ethidium bromide. DNA bands were
visualized by UV light and digitally photographed using a
gel documentation system and Quantity-one™ image ana-
lysis software (Bio-Rad, USA). Quantity-one™ software
was used to quantify the density of bands for comparison
between experimental groups.
Statistical analysis
Non-parametric Mann-Whitney tests were used to test
for statistical differences between patients and controls
for all apoptosis assays. Pearson, or Spearman rank
correlations were used to test the dependence of vari-
ables where appropriate. All analyses were performed
using the GraphPad Prism (V5) software package
(GraphPad Software Inc., USA).
Results
Elevated phosphatidylserine externalization in RA-PBL
Translocation of phosphatidylserine residues from the
inner leaflet of the plasma membrane to the outer leaflet
o ft h ep l a s m am e m b r a n ei sa n early apoptotic event.
Annexin-V is a specific and strong phosphatidylserine-
binding protein [24] that detects cells undergoing apopto-
sis. The annexin-V assay showed that apoptosis was signif-
icantly higher (p < 0.05) in RA PBL than in healthy
controls ex vivo. When analyzed separately, apoptosis in
RA CD4
+ PBL was approximately 3.5-fold higher than
controls (26.3 ± 1.6% vs. 7.6 ± 0.8%). The highest apopto-
sis values were recorded in the RA CD19
+ PBL, which
were approximately 4-fold higher than controls (60.5 ±
7.4% vs. 16.1 ± 1.9%; Table 2).
Late stage apoptotic and/or necrotic cells which take
up PI were distinguished from PBL which were exclu-
sively positive for annexin-V (Figure 1). The percent of
RA-PBL positive for PI was extremely low (0.4% ± 0.10)
and did not differ significantly from controls (0.2 ± 0.03;
p = 0.1085, unpaired t test).
To examine the effect of elevated apoptosis on the
number of circulating lymphocytes in RA patients, we
statistically tested whether total PBL apoptosis correlated
with absolute lymphocyte counts. We found no statisti-
cally significant relationship between total PBL apoptosis
and absolute lymphocyte counts (Figure 2).
In order to determine whether disease duration
affected apoptosis levels in our study cohort, we exam-
ined whether apoptosis correlated with disease duration.
We found that levels of apoptosis did not correlate with
disease duration (Spearman rank correlation, r = -0.1539,
p = 0.2962). Patients were then grouped, i.e. patients with
RA for < 10 years (n = 22) and > 10 years (n = 28).
Although total PBL apoptosis was slightly higher in
patients with RA for less than 10 years (30.6% vs. 27.8%),
disease duration did not significantly affect apoptosis in
Table 2 Annexin-V analysis of apoptosis in peripheral
lymphocyte sub-populations from South African
rheumatoid arthritis patients and race-matched controls
ex vivo
Cell
population
Patients [Mean % (SEM)] Controls [Mean % (SEM)]
Total PBL 30.0 (1.5)* 7.2 (0.9)
CD4
+ PBL 26.3 (1.6)* 7.6 (0.8)
CD19
+ PBL 60.5 (7.4)* 16.1 (1.9)
* Significant difference (p < 0.05; Mann-Whitney test). CD4, cytotoxic
T-lymphocyte marker; CD19, pan B-lymphocyte marker.
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Welch correction).
Patients were at various stages of treatment when
sampled. They were distributed among three treatment
categories, namely, patients on methotrexate (MTX) alone
(n = 13), MTX together with steroidal drugs (n = 29) and
those on other disease-modifying-anti-rheumatic-drugs
(DMARD, n = 8). There was no significant difference in
PBL apoptosis (p = 0.6967, one way ANOVA; Figure 3)
when compared across different treatments. Experimental
values measured in our patient cohort were independent
of treatment.
Higher percentage of RA-PBL with CD95/Fas on plasma
membrane
To determine whether the elevated apoptosis measured
in our patient cohort was associated with receptor
mediated apoptosis-inducing signals, we tested for the
presence of CD95/Fas on PBL. The proportion of PBL
expressing CD95/Fas was significantly higher in RA
patients compared to controls (p = 0.0317; Mann Whit-
ney test; Figure 4).
Increased expression of Fas pathway associated
transcripts in RA-PBLs
To investigate apoptotic signaling pathways in RA-PBLs,
we analyzed the expression profiles of 84 genes involved in
the induction and/or transduction of apoptosis. The high-
est fold change differences were observed in genes asso-
ciated with the Fas-mediated apoptotic pathway (Figure 5).
RA-PBL showed low levels of activation
Since CD95/Fas is associated with AICD in lymphocytes,
we examined the activation status of circulating lympho-
cytes in our study cohort by monitoring the proportion
of PBL positive for the CD69 activation marker. Interest-
ingly, despite high apoptosis levels, RA patients had a
lower percent of PBL positive for CD69 compared to
controls, however, this did not reach statistical signifi-
cance (p > 0.05; Mann Whitney test; Figure 6).
Elevated caspase activity in RA-PBL
Despite low luminescent signals recorded for executioner
caspase 3/7 activity, there was approximately 3-fold
higher activity in RA PBL compared to healthy controls.
This difference in activity reached statistical significance
(p < 0.01; Mann-Whitney test; Figure 7A). Caspase-9
activity produced strong luminescent signals in both
patients and controls, but was not statistically significant
between these groups (Figure 7B).
Elevated HSP70 in RA-PBL
Since HSP70 is an inducible protein which can modulate
apoptosis signals, the levels of HSP70 in PBL were
Figure 2 Absolute lymphocyte counts did not correlate with
peripheral lymphocyte apoptosis in RA patients. Correlation co-
efficient r = -0.08956; p value = 0.5362; Pearson r correlation.
Figure 3 Percent of peripheral blood lymphocytes with
translocated phosphatidyl serine according to treatment in RA
patients (MTX: methotrexate; DMARD: disease modifying anti-
rheumatic drug).
Figure 4 Percent CD95/Fas positive peripheral lymphocytes
from South African rheumatoid arthritis patients and healthy
race-matched controls. PBL were analyzed by flow cytometry. Data
is represented as mean percent + standard error of the mean. *
Significant difference, p = 0.0317; Mann Whitney test.
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guished between PBL with high or low levels of intra-cel-
lular HSP70 as a function of mean fluorescence intensity
(Figure 8A). Our data showed that the proportion of PBL
with detectable levels of intra-cellular HSP70 was signifi-
cantly higher in RA patients compared to controls (p =
0.0001; Mann-Whitney test; Figure 8B). To confirm these
data, western blot analysis for HSP70 was performed on
total PBL protein (Figure 8C). Band analyses showed that
HSP70 levels were significantly elevated in RA patients (p
= 0.0090; unpaired t-test; Figure 8D). We next investi-
gated whether there was an association between HSP70
levels and phosphatidylserine externalization in RA-PBLs.
Our data showed a strong positive correlation between
HSP70 levels and phosphatdylserine externalization in
RA-PBLs (Figure 9).
No DNA fragmentation in RA-PBL
DNA fragmentation, a typical molecular feature of apopto-
sis, occurs due to nuclease mediated cleavage of genomic
DNA into oligonucleosomal fragments in multiples of
approximately 200 base pairs. Nuclease activity is induced
towards the latter stages of apoptosis by upstream apopto-
sis mediators such as caspase-3. The characteristic apopto-
sis DNA fragmentation pattern was not observed in
patient or control samples following agarose gel electro-
phoresis. All DNA bands were of high molecular weight
and intact with no signs of apoptosis-induced DNA
damage (Figure 10).
Discussion
The fine balance between cell survival and cell death is
essential for homeostasis in multi-cellular organisms.
Apoptosis is the major mechanism of physiological cell
death which facilitates deletion of unwanted or damaged
cells. It plays a central role in the immune system in both
the maintenance of self-tolerance and homeostatic con-
trol of lymphocyte populations [4]. The immune system
relies on apoptosis for its functional integrity at multiple
levels, and consequently, stringent regulation of these
pathways is imperative. Immunological tolerance is
promoted by carefully directed apoptosis in self-reactive
T-lymphocyte clones during their maturation in the thy-
mus [25]. Immune learning continues while lymphocytes
are in peripheral circulation, since not all antigenic
combinations are encountered in the thymus. The precise
mechanisms of peripheral immune learning are
unknown, but may also involve deletion of self-reactive
lymphocytes by apoptosis whilst in circulation [26]. It is
likely that defects in peripheral immune learning may
lead to autoimmunity. Lymphocyte death is tightly regu-
lated and there are detrimental consequences when regu-
latory mechanisms are compromised. For instance,
abnormal increases in apoptosis can cause immunodefi-
ciency [27]; while a failure to undergo apoptosis can lead
to development of autoimmunity [28].
In RA, there is compelling evidence to show that a
compromise in lymphocyte apoptosis contributes to the
persistence of these cells at inflamed joints [6]. Inflamma-
tion is normally resolved by carefully directed apoptosis
of invading immune cells [4]. In RA however, the mole-
cular interactions between synovial cells and infiltrating
lymphocytes have been shown to protect against apopto-
sis in the synovium [8].
Little is known about the biological status of circulating
lymphocytes prior to synovial recruitment in RA. Our
studies therefore focused on circulating lymphocytes,
which perpetuate the autoimmune manifestations of RA.
We assessed PBL apoptosis since they are exposed to a
myriad of pro-inflammatory cytokines and acute-phase
proteins. This may compromise functional integrity
Figure 5 Increased expression of Fas pathway associated
genes in RA-PBL. Data is represented as mean fold change +
standard error of the mean.
Figure 6 Activation status of peripheral lymphocytes were
monitored by examining presence of CD69 on cell surface.
Data is represented as mean percent + standard error of the mean.
No statistical significance was established between RA patients and
control subjects (p > 0.05; Mann Whitney test).
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matoid synovium. Our data showed that early markers of
apoptosis were elevated in total lymphocytes from RA
patients. This trend was mimicked in CD4
+ lymphocytes,
but more so in CD19
+ B-lymphocytes; where more than
half of this lymphocyte population showed apoptotic
features whilst in circulation. This suggests that abnorm-
alities in the regulation of lymphocyte apoptosis may
occur early in RA, prior to synovial infiltration.
Our data also showed minor elevations in control PBL
apoptosis compared to baseline values previously reported
in the literature. This may be indicative of normal baseline
Figure 7 Apoptotic protease activity in peripheral lymphocytes. A: Higher caspase 3/7 activity in RA-PBL despite low luminescent signals. B:
Initiator caspase 9 activity was high in both study groups but not significantly different. Data is expressed as mean relative light units +
standard error of the mean. * Significant difference, p < 0.01; Mann-Whitney test.
Figure 8 Detection of HSP70 in peripheral lymphocytes. A: Mean fluorescence intensity histogram for intra-cellular detection of HSP70 by
flow cytometry. B: Proportion of PBL with detectable levels of HSP70 was higher in RA patients (*p= 0.0001; Mann-Whitney test). C:
Representative western blot analysis of HSP70 in total PBL protein. D: HSP70 levels significantly elevated in RA patients (*p= 0.0090; unpaired t-
test).
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extremely sensitive to physiological changes. Considering
baseline apoptotic noise, it is likely that observations of
relative apoptotic changes, which deviate significantly in
disease phenotypes, may in fact indicate an integral role
for the apoptosis in disease progression or etiology.
The elevated levels of PBL apoptosis observed in our
patient cohort was not associated with AICD, since only a
small percentage of lymphocytes showed detectable levels
of the CD69 activation marker. CD69 is a transiently
expressed membrane receptor early during lymphocyte
activation, but is also selectively expressed in chronic
inflammation [29]. Interestingly, engagement of the CD69
receptor was shown to trigger apoptosis in multiple cell
types [30], but despite persistent expression in chronic
inflammatory infiltrates, lymphocyte apoptosis was inhib-
ited. Evidence from molecular and cellular studies showed
that T-lymphocyte activation was altered in RA [31]. This
may account for the high levels of RA-PBL apoptosis
observed in our patients where signs of early lymphocyte
activation were relatively absent.
Under normal conditions, hea l t h ym i t o c h o n d r i ah a v e
polarized electronegative transmembrane gradients due to
oxidative phosphorylation reactions. We have previously
reported that mitochondrial depolarization was elevated in
RA-PBL [32]. Loss of transmembrane potential alters
mitochondrial permeability which results in the release of
proteins such as cytochrome c and second-mitochondrial
activator of caspases/direct-inhibitor-of-apoptosis-binding-
protein-with-low-PI (Smac/DIABLO) into the cytoplasm
[33]. In the cytoplasm, cytochrome c binds to apoptotic-
protease-activating-factor (Apaf-1) and pro-caspases, lead-
ing to ATP-dependant formation of the apoptosome [34].
The apoptosome is a potent activator of initiator caspases,
in particular caspase-9. Activated caspase-9 in turn facili-
tates activation of executioner caspases (primarily caspase-
3 and caspase-7), which co-ordinate proteolytic break-
down of apoptotic cells. Engagement of CD95/Fas with its
ligand leads to activation of caspase-8 following recruit-
ment of Fas-associated-death-domain-protein (FADD).
This can signal apoptosis via two well-described pathways:
(i) direct activation of caspase-3; or (ii) alteration of mito-
chondrial transmembrane potential via Bcl-2 homology-3
(BH3)-interacting-death-domain (BID) agonist, which
initiates the mitochondrial apoptosis cascade [35,36]. The
CD95/Fas signaling pathway ultimately culminates in the
activation of executioner caspases, which is a molecular
hallmark of apoptosis.
Although caspase-3/7 activity was significantly higher
in RA patients, these activities remained relatively low.
This suggests that there may be perturbations in the sig-
naling pathways which activate executioner caspases in
these cells. A possible mechanism may involve HSP
mediated interference between apoptosis initiator signals
and their down-stream targets.. Activation of caspase-3
for instance, is suppressed by HSP27 since it binds to
pro-caspase-3, thus preventing its activation by caspase-9
[37]. Alternatively, HSP27 may sequester cytochrome c
from Apaf-1, thus preventing assembly of the apopto-
some [38,39]. In addition the small HSP ab crystalline,
suppresses cytochrome c-mediated autoactivation of cas-
pase-3, by direct interaction with the enzyme to prevent
its complete processing [40]. HSP70 has been implicated
in the inhibition of apoptosome formation [20,41], but
may also inhibit caspase-dependent events that occur
later in apoptosis [42]. Chromosomal DNA is digested by
caspase-activated-DNase/DNA fragmentation factor
Figure 9 HSP70 levels correlate with RA-PBL apoptosis.
Correlation co-efficient r = -0.8121; p value < 0.0001; Pearson r
correlation.
Figure 10 DNA fragmentation assay in peripheral lymphocytes
by agarose gel electrophoresis. M: molecular weight marker; lane
1: control PBL DNA; lane 2: positive control; lane 3, 4, 5: RA-PBL
DNA.
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Page 9 of 1140 (CAD/DFF40) during the final stages of apoptosis,
upon activation by caspase-3 [43]. The enzymatic activity
and structural integrity of CAD/DFF40 was reported to
be regulated by HSP70 and HSP40 [44]. Over-expression
of these HSPs may prevent nuclear degradation regard-
less of up-stream pro-apoptotic events. We have recently
reported in the same population of patients that RA-PBL
sustain significant damage due to oxidative stress [32].
This may induce cellular stress responses which increase
the expression of HSPs, which could possibly modulate
apoptotic signal cascades. This may have contributed to
the lack of lymphocyte DNA fragmentation observed in
our patient cohort, despite early signs of apoptosis. Ear-
lier studies by Szodoray et al (2003) examined nuclear
condensation as a measure of apoptosis in circulating RA
T-lymphocytes bearing typical apoptotic markers (CD95/
Fas, Bax, Bcl-2 and TNF receptor) [45]. These investiga-
tions showed decreased levels of nuclear condensation in
T-lymphocytes and were thus interpreted to have
decreased rates of CD95/Fas mediated apoptosis. In addi-
tion, lymphocytes positive for Bax protein also showed
decreased apoptosis frequency. The study concluded that
the reduced susceptibility to CD95-mediated apoptosis
may contribute to the expansion of an activated CD4
+
lymphocyte sub-population and thus to the maintenance
of peripheral autoreactive T-cell clones in RA [45].
Furthermore, the molecular features of apoptosis mea-
sured in RA-PBL did not translate to reduced numbers of
circulating lymphocytes in our patient cohort. This was
indicated by a lack of statistically significant correlation
between absolute lymphocyte counts and total PBL apop-
tosis. This observation supports the notion that the apop-
totic program may not be fully executed despite early
molecular signs of apoptosis in RA-PBL. Albeck et al
(2008) recently reported that although cells may exhibit
molecular hallmarks of apoptosis, they may not be com-
mitted to fully executing the program and may recover
from pro-apoptotic signals [46]. Although the mechanisms
of apoptosis recovery are not fully understood, caspase
inhibition via the X-linked-inhibitor-of-apoptosis-protein
(XIAP) and proteosomal degradation of executioner cas-
pases seem to play a role [47]. Interestingly, Rehm et al
(2006) also described a state in which cells may exist with
partial caspase-dependent degradation of their proteomes
without outward manifestations of apoptotic features [48].
In RA, it is likely that although apoptosis is initiated in cir-
culating lymphocytes, these cells may not be committed to
executing the molecular program fully and cellular inter-
actions at the synovium exacerbate their anti-apoptotic
phenotype. In addition, chronically elevated lymphocyte
counts may occur as a result of apoptosis induced com-
pensatory proliferation. Recent studies have elucidated
non-apoptotic functions of both initiator and executioner
caspases. These are involved in generating growth
stimulating and compensatory cell proliferation signals via
alternate MAPK cascades [49]. Death receptors have also
been implicated in non-cytotoxic responses which include
regulation of cell proliferation, growth stimulation and
production of pro-inflammatory chemokines. Evidence
already indicates that engagement of death receptors in
the rheumatoid synovium promotes cell proliferation
instead of cell death [50].
Although not fully understood, similar mechanisms
may operate and contribute to the maintenance of auto-
reactive lymphocyte clones in autoimmune diseases
where apoptosis is elevated in peripheral circulation.
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